BusinesseClinical Data Volume and Diversity Pose Increasing Challenges and Delays, According to the Tufts Center for the Study of Drug DevelopmentBy Nasdaq OMXJan 9, 2018, 2:01 PM UTC
BusinessSanuwave Receives FDA De Novo Decision to Immediately Market the Dermapace System for the Treatment of Diabetic Foot Ulcers in the U.S.By Nasdaq OMXJan 2, 2018, 1:01 PM UTC
BusinessHorizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic CystinosisBy Nasdaq OMXDec 27, 2017, 1:00 PM UTC
BusinessRhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)By Nasdaq OMXDec 22, 2017, 1:00 PM UTC
BusinessAXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND SubmissionBy Nasdaq OMXDec 12, 2017, 2:01 PM UTC
BusinessRhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)By Nasdaq OMXDec 9, 2017, 1:00 PM UTC
BusinessOmni Health Announced Development of New Drug CandidateBy Nasdaq OMXDec 5, 2017, 11:00 AM UTC
BusinessSafetyChain Software Launches Supplier Analytics for Easier Management of Vendor Approval ProgramsBy Nasdaq OMXDec 4, 2017, 10:05 PM UTC
